J
Janux Therapeutics, Inc. (JANX)
NGM – Real vaqt narxi. Valyuta: USD
14.41
+0.18 (1.26%)
Yopilishda: May 12, 2026, 4:00 PM EDT
14.10
-0.31 (-2.15%)
Bozor oldidan: May 13, 2026, 6:11 AM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NGM – Real vaqt narxi. Valyuta: USD
14.41
+0.18 (1.26%)
Yopilishda: May 12, 2026, 4:00 PM EDT
14.10
-0.31 (-2.15%)
Bozor oldidan: May 13, 2026, 6:11 AM EDT
Janux Therapeutics, Inc., klinik bosqichdagi biotexnologiya kompaniyasi, saraton kasalligiga chalingan bemorlarni davolash uchun Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr) va Adaptive Immune Response Modulator (ARM) platformalari texnologiyalariga asoslangan immunoterapiyalarni ishlab chiqadi. Kompaniyaning klinik nomzodlari orasida prostata-spetsifik membranali antigen yoki PSMA-TRACTr bo'lgan JANX007 mavjud bo'lib, u metastatik kastratsiyaga chidamli prostata saratoni va boshqa o'smalarning qon tomirlarini davolash uchun kattalarda 1-faza klinik sinovlarida; va epidermal o'sish omili retseptorining JANX008 mavjud bo'lib, u kolorektal saraton, bosh va bo'yinning skvamoz hujayrali karsinomasi, mayda hujayrali bo'lmagan o'pka saratoni, buyrak hujayrali karsinomasi, mayda hujayrali o'pka saratoni, oshqozon osti bezi o'tkir adenokarsinomasi va uch tomonlama negativ ko'krak bezi saratoni kabi turli qattiq saraton turlarini davolash uchun 1-faza klinik sinovlarida. Kompaniya, shuningdek, avtoimmunitet kasalliklari uchun ishlab chiqilgan, CD19ga yo'naltirilgan adaptiv immunitet javobining modulatori bo'lgan JANX011ni ishlab chiqadi. Kompaniya TRACTr mahsulot nomzodlarini ishlab chiqish uchun Merck Sharp & Dohme Corp. bilan strategik tadqiqot hamkorlik shartnomasiga; va Bristol Myers Squibb bilan bir nechta inson saraton turlarida ifodalangan tasdiqlangan qattiq o'simta antigeniga yo'naltirilgan, noma'lum, yangi o'simta tomonidan faollashtirilgan terapevtik vositani ishlab chiqish va tijoratlashtirish bo'yicha shartnomaga ega. Janux Therapeutics, Inc. 2017 yilda tashkil etilgan va uning shtab-kvartirasi San-Diegoda, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. David Alan Campbell Ph.D. | President, Co-Founder, CEO & Director |
| Dr. Thomas Diraimondo Ph.D. | Chief Scientific Officer |
| Dr. William Y. Go M.D., Ph.D. | Chief Medical Officer |
| Mr. Charles M. Winter | Chief Technical Officer |
| Mr. James Pennington | General Counsel & Corporate Secretary |
| Mr. Matt Whitmire | Vice President of Finance |
| Ms. Janeen Doyle | Chief Corporate & Business Development Officer |
| Ms. Maria Dobek | Vice President of Accounting |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-07 | 8-K | janx-20260507.htm |
| 2026-04-28 | DEFA14A | janx_defa14a_2026_non_xb.htm |
| 2026-04-28 | ARS | 2025_10-k_ars.pdf |
| 2026-02-26 | S-8 | janx-20260226.htm |
| 2026-02-26 | 8-K | janx-20260226.htm |
| 2026-01-22 | 8-K | janx-20260121.htm |
| 2025-11-06 | 10-Q | janx-20250930.htm |
| 2025-09-19 | 8-K | janx-20250918.htm |
| 2025-08-07 | 8-K | janx-20250807.htm |
| 2025-08-07 | 10-Q | janx-20250630.htm |